Collegium Pharmaceutical Stock News

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2020 Results - Earnings Call Transcript

These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.

Today we will run through one way of estimating the intrinsic value of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by...

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 – – Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020 –– Xtampza ® ER Net Revenue

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...

On Wednesday, August 05, Collegium Pharmaceutical (NASDAQ: COLL) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.Earnings an

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STOUGHTON, Mass., July 21, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.

Collegium unfortunately had to cut the 2020 guidance in a small way  alongside first quarter earnings report.

AMRX vs. COLL: Which Stock Is the Better Value Option?

Investment analysts at Needham & Company LLC began coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report issued on Monday, TipRanks reports. The firm set a “buy” rating

Legal & General Group Plc lowered its stake in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 19.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The instit